OxPL-apo
Biomarker1 paper2 findings
- Human trial1
Interventions
1Lepodisiran
downin humans1Moderate certainty
1 study
Lepodisiran
downin humans1Moderate certainty
Lepodisiran decreases OxPL-apo in humans (-94.2% (95% CI: -95.7% to -92.2%)).
Human trialplacebo-adjusted geometric mean in 400-mg dose group at day 240400 mgday 240n = 213
Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a) · Journal of the American College of Cardiology · 31 Aug 2026
Effects
1C-reactive protein
no changein humans1
1 study
C-reactive protein
no changein humans1
OxPL-apo has no effect on C-reactive protein in humans.
Human trialpost hoc trial analysisday 360n = 213
Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a) · Journal of the American College of Cardiology · 31 Aug 2026
Latest
1Journal of the American College of CardiologyHuman trial